Pharmaceutical News

RSS

Seattle Genetics collaborates with Bayer HealthCare for new antibody-drug conjugate

Seattle Genetics, Inc. today announced that it has entered into a new antibody-drug conjugate (ADC) collaboration with Bayer HealthCare (Bayer). Under the latest relationship, Bayer will pay upfront and option exercise fees of up to $20 million for worldwide rights to utilize Seattle Genetics' auristatin-based ADC technology with antibodies to several oncology targets.

25 Jun 2013

Study shows risk of Guillain-Barre syndrome after vaccination is extremely low

Patients are not at increased risk of Guillain-Barr- syndrome in the six-week period after vaccination with any vaccine, including influenza, according to a Kaiser Permanente study published in Clinical Infectious Diseases.

25 Jun 2013

IAIM seeks to support immunization managers to achieve vaccination goals

The Sabin Vaccine Institute today announced the launch of the newly-formed International Association of Immunization Managers (IAIM). With the support of a five-year grant from the Bill & Melinda Gates Foundation, IAIM's objective is to help drive the achievement of national, regional and international immunization goals, including those in the Global Vaccine Action Plan (GVAP), by fostering forward-thinking and superior management of immunization programs.

25 Jun 2013

Study finds that triple therapy corrects two core defects in type 2 diabetes

Patients with type 2 diabetes fare significantly better if they are started on three medications at the time of diagnosis than if they are prescribed a single drug and have other therapies added later, a San Antonio researcher said June 22 at the 73rd Scientific Sessions of the American Diabetes Association in Chicago.

25 Jun 2013

Rebiotix receives FDA Fast Track designation for RBX2660 to treat patients with CDI

Rebiotix Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track designation for the investigation of RBX2660 (microbiota suspension), intended for the treatment of recurrent Clostridium difficile infection.

25 Jun 2013

Advaxis seeks ADXS-HPV Orphan Drug Designation for treatment of HPV-associated anal cancer

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has submitted an Application for Orphan Drug Designation with the U.S. Food and Drug Administration Office of Orphan Products Development for ADXS-HPV, its lead drug candidate, for the treatment of human papillomavirus-associated anal cancer.

25 Jun 2013

Study finds U-shaped association between consumption of fish and risk of developing AF

Moderation seems to be key when it comes to eating fish to prevent atrial fibrillation according to an observational study presented at the EHRA EUROPACE congress held 23 to 26 June in Athens, Greece.

25 Jun 2013

Patients with type2 diabetes, renal impairment have less hypoglycemia with JANUVIA compared to sulfonylurea

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc pooled analysis showing patients with type 2 diabetes and mild renal impairment treated with JANUVIA- (sitagliptin) 100 mg once-daily achieved similar blood sugar reductions as those treated with the sulfonylureas glipizide or glimepiride, with significantly fewer events of hypoglycemia (low blood sugar), and with weight loss instead of weight gain.

24 Jun 2013

Boehringer submits application to EMA for use of Pradaxa for treatment of acute DVT, PE

Boehringer Ingelheim today announced the submission of an application to the European Medicines Agency (EMA) for use of Pradaxa (dabigatran etexilate) for the treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE.

24 Jun 2013

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a new study in which linagliptin demonstrated statistically significant reductions in blood glucose levels (HbA1c) after 12 weeks (the study's primary endpoint) in adults with type 2 diabetes (T2D) with moderate to severe renal impairment, compared with placebo. Most patients had T2D for more than ten years (76 percent) and were on insulin (86 percent).

24 Jun 2013

HSG conducts clinical trial with novel drug formulation for treating Huntington disease

The Huntington Study Group (HSG), under the leadership of Samuel Frank, MD, Principal Investigator, (Boston University School of Medicine) and Claudia Testa, MD, PhD, co-Principal Investigator (Virginia Commonwealth University), is conducting a clinical trial with a formulation of the novel drug SD-809 in the treatment of HD the United States and Canada.

24 Jun 2013

Administering large iron doses over short period of time increases patients' risk of infections

While intravenous iron is critical for maintaining the health of many dialysis patients, administering large doses over a short period of time increases patients' risk of developing serious infections, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). Smaller doses given for a longer period of time appears to be much safer.

24 Jun 2013

EC grants marketing authorization for XTANDI capsules for treating advanced prostate cancer

Astellas Pharma Europe Ltd., the European Headquarters of Tokyo-based Astellas Pharma Inc. (TSE:4503), and Medivation, Inc. announced that following the regulatory review process by the European Medicines Agency (EMA) and a positive opinion from the Committee for Medicinal Products for Human Use on April 25, 2013, the European Commission (EC) has granted the marketing authorization for XTANDI™ (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.

24 Jun 2013

First Edition: June 21, 2013

Today's headlines include reports about the rebates some insurers will provide to consumers as a result of a health law provision.

21 Jun 2013

FDA approves use of Plan B One-Step pill for all women with child-bearing potential

Today, the U.S. Food and Drug Administration announced it has approved the use of Plan B One-Step (levonorgestrel) as a nonprescription product for all women of child-bearing potential.

21 Jun 2013

Medicago produces Rotavirus VLP vaccine candidate using plant-based manufacturing platform

Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced the successful production of a Rotavirus VLP vaccine candidate comprising all four structural antigens of rotavirus (VP2, VP4, VP6 and VP7) using Medicago's plant-based manufacturing platform.

20 Jun 2013

Nearly 70% of Americans use at least one prescription drug, say researchers

Nearly 70 percent of Americans are on at least one prescription drug, and more than half take two, Mayo Clinic researchers say. Antibiotics, antidepressants and painkilling opioids are most commonly prescribed, their study found. Twenty percent of patients are on five or more prescription medications, according to the findings, published online in the journal Mayo Clinic Proceedings.

20 Jun 2013

NUS researchers develop highly realistic 3-D tumor model to track progress of drug therapy

A team of NUS researchers from the Departments of Bioengineering and Orthopaedic Surgery has developed a highly realistic three-dimensional (3-D) tumour model. As it replicates the conditions in the body, it is able to track the effectiveness and progress of drug therapy.

20 Jun 2013

Treating bacteria with silver compounds boosts efficacy of old antibiotics

Slipping bacteria some silver could give old antibiotics new life, scientists at the Wyss Institute for Biologically Inspired Engineering at Harvard University reported June 19 in Science Translational Medicine.

20 Jun 2013

Diapocynin antioxidant protects neurobehavioral function in mice with Parkinson's disease

Diapocynin, a synthetic molecule derived from a naturally occurring compound (apocynin), has been found to protect neurobehavioral function in mice with Parkinson's Disease symptoms by preventing deficits in motor coordination.

20 Jun 2013

Pharmaceutical News

Seattle Genetics collaborates with Bayer HealthCare for new antibody-drug conjugate

Study shows risk of Guillain-Barre syndrome after vaccination is extremely low

IAIM seeks to support immunization managers to achieve vaccination goals

Study finds that triple therapy corrects two core defects in type 2 diabetes

Rebiotix receives FDA Fast Track designation for RBX2660 to treat patients with CDI

Advaxis seeks ADXS-HPV Orphan Drug Designation for treatment of HPV-associated anal cancer

Study finds U-shaped association between consumption of fish and risk of developing AF

Patients with type2 diabetes, renal impairment have less hypoglycemia with JANUVIA compared to sulfonylurea

Boehringer submits application to EMA for use of Pradaxa for treatment of acute DVT, PE

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

HSG conducts clinical trial with novel drug formulation for treating Huntington disease

Administering large iron doses over short period of time increases patients' risk of infections

EC grants marketing authorization for XTANDI capsules for treating advanced prostate cancer

First Edition: June 21, 2013

FDA approves use of Plan B One-Step pill for all women with child-bearing potential

Medicago produces Rotavirus VLP vaccine candidate using plant-based manufacturing platform

Nearly 70% of Americans use at least one prescription drug, say researchers

NUS researchers develop highly realistic 3-D tumor model to track progress of drug therapy

Treating bacteria with silver compounds boosts efficacy of old antibiotics

Diapocynin antioxidant protects neurobehavioral function in mice with Parkinson's disease

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News